In May 2016, the company announced that it was relocating its hemophilia drug trafficking (Eloctate and Alprolix) to a limited company. [22] In August, the company announced that the outsourced company would be called Bioverativ to show its legacy with Biogen. [23] The company trades on the NASDAQ stock exchange under the symbol of ticker BIVV[24][25] and will be relocated in early 2017. [26] Bioverativ was acquired by Sanofi in 2018. This press release contains forward-looking statements, including statements about Biogen Idec`s expectations and mission to develop treatments for people with Alzheimer`s disease by working with Eisai. These forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “estimate,” “wait,” “predict,” “anticipate,” “may,” “plan,” “want” and other words and terms of similar meaning. You should not rely too much on these statements. These statements involve risks and uncertainties, which could lead to a significant discrepancy in actual results from the results reflected in these statements, including risks and uncertainties related to the development and commercialization of drugs, Biogen Idec`s reliance on third parties over which it may not always be fully controlled, and other risks and uncertainties described in the risk factors section of Biogenec Id`s latest annual or quarterly report, submitted to the Securities and Exchange Commission. These statements are based on current beliefs and expectations and are not available until the date of this press release.

Biogen Idec undertakes no public update of any forward-looking statements. Haruo Naito, President and CEO of Eisai Co., Ltd. added: “There is an urgent need to develop AD therapies that suppress disease progression in order to effectively relieve the emotional burden of suffering and insecurity suffered by patients and their families, as well as the financial burden of society as a whole with respect to the enormous costs of patient care and care. Eisai remains very focused on the development of these therapies, based on the knowledge and experience he has gained through his development of the anti-AD agent Aricept ®. By working with Biogen Idec, a neurodegenerator company, I believe we can develop our existing research and development capabilities for the development of next-generation AD treatments, accelerating the development of promising therapies and increasing benefits for AD patients worldwide. These statements involve risks and uncertainties that could lead to a significant divergence in actual results from those expressed in these statements, including, but not limited to, uncertainty about the potential to achieve the expected benefits and potential of Biogen`s cooperation agreement with Eisai; The risk of unforeseen costs or delays uncertainty about the success of the development and potential commercialization of aducanumab, Elenbecestat and/or BAN2401, which may be dispelled, among other things, by unexpected concerns arising from additional data or analysis, the occurrence of adverse security events, non-compliance with regulatory authorities in certain legal systems, the lack of protection and implementation of data relating to biogens, intellectual property and other intellectual property rights, and uncertainties related to intellectual property rights and challenges; and risks to third-party cooperation. The above presents many, but not all, factors that could lead to the actual results of each forward-looking statement differing from Biogen`s expectations.